NUCLEOLIN and cancer: Several new rDNA transcription inhibitors are in early clinical studies, such as CX-3543, BMH-21, and CX-5461.287–289, CX-3543 binds to the G4 sequence and disrupting the interaction of the rDNA G4 structure with Ncl, thereby inhibiting RNA Pol I function and inducing apoptosis in cancer cells.